renin-angiotensin system blockade and enzyme replacement therapy, and showed a striking decrease in urine protein excretion when amiloride was added to his other medications. Fabry disease (22) as well as many other forms of proteinuric kidney diseases (2) are being recognized as fundamentally, or at least initially, as a podocyte disease.
Svenningsen et al. (20) previously reported a tendency to an increased urinary plasminogen/plasmin ratio in nephrotic rats treated with amiloride, and in an issue of the American Journal of Physiology-Renal Physiology they hypothesized that uPA and plasminogen are "aberrantly" filtered in nephrotic syndrome and that amiloride could prevent tubular activation of plasminogen to plasmin by inhibiting uPA. They measured sodium balance, uPA protein and activity, and amiloride concentration in urine from rats with puromycin aminonucleosideinduced nephrotic syndrome (18) . Amiloride (2 mg·kg Ϫ1 ·4 h Ϫ1 ) resulted in urinary concentrations between 10 and 20 M, with significant reduction in uPA activity, plasminogen activation, protease activity, and sodium retention in this rat model of nephrotic syndrome. In contrast to previous reports (23, 28) , total urinary protein was not decreased, which seems to be typical of acute experimental nephrotic models in rodents but not in humans or longer-term rodent models like 5/6th nephrectomy (28) .
The current study (18) and other recent papers from this group (1, 19, 27) have emphasized the dual effects of amiloride; directly on ENaC through inhibition of channel blockade and indirectly through its novel effects on uPA activity with consequent attenuation of posttranslational ENaC activation. While these approaches are important for understanding the regulation of ENaC activity in pathologic conditions such as nephrotic syndrome, they do not address the upstream causes of proteinuria and the remarkable "off-target" effects of amiloride that appear to involve the interactions between uPA, its receptor, and ␤3-integrin that play a critical role in anchoring the podocytes to the glomerular basement membrane (12, 23, 28) . Finally, plasmin is a profibrotic molecule that could contribute to scarring and fibrosis in proteinuric states (29) . By inhibiting plasmin, amiloride could attenuate scarring and fibrosis in a variety of proteinuric conditions.
The therapeutic window has been opened a bit wider for amiloride; a fresh look is needed to define its unique targets and activities as well as its place among inhibitors of the renin-angiotensin system, mindful of the well-described problems with hyperkalemia (8) , and also the previous observations that amiloride can stimulate aldosterone secretion (25) , which could attenuate the inhibitory effect of amiloride on ENaC activity.
